Key statistics
SmartText not available for this item.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | -- |
---|---|
High | 586.00 |
Low | 586.00 |
Bid | -- |
Offer | -- |
Previous close | 586.00 |
Average volume | -- |
---|---|
Shares outstanding | 124.32m |
Free float | 118.76m |
P/E (TTM) | -- |
Market cap | 2.30bn USD |
EPS (TTM) | -4.65 USD |
Data delayed at least 20 minutes, as of Jul 20 2023 12:30 BST.
More ▼
Press releases
- Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome
- Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran
- Arrowhead Pharmaceuticals to Webcast 2024 Fiscal Year End Results
- Arrowhead Pharmaceuticals to Participate in Upcoming November 2024 Conferences
- Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, ‘We’ll Get There Soon,’ to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome
- Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
- Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity
- Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran
- Arrowhead Pharmaceuticals Presents New Pivotal Phase 3 Data at ESC 2024 from PALISADE Study of Plozasiran in Patients with Familial Chylomicronemia Syndrome
More ▼